Celcuity (CELC) Competitors $13.63 +0.01 (+0.07%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$13.71 +0.08 (+0.59%) As of 07/11/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELC vs. ADUS, PACS, ARDT, LFST, PGNY, GRAL, NHC, TDOC, VRDN, and AHCOShould you be buying Celcuity stock or one of its competitors? The main competitors of Celcuity include Addus HomeCare (ADUS), PACS Group (PACS), Ardent Health (ARDT), LifeStance Health Group (LFST), Progyny (PGNY), GRAIL (GRAL), National HealthCare (NHC), Teladoc Health (TDOC), Viridian Therapeutics (VRDN), and AdaptHealth (AHCO). These companies are all part of the "healthcare" industry. Celcuity vs. Its Competitors Addus HomeCare PACS Group Ardent Health LifeStance Health Group Progyny GRAIL National HealthCare Teladoc Health Viridian Therapeutics AdaptHealth Addus HomeCare (NASDAQ:ADUS) and Celcuity (NASDAQ:CELC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk. Which has better valuation & earnings, ADUS or CELC? Addus HomeCare has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddus HomeCare$1.15B1.77$73.60M$4.4325.04CelcuityN/AN/A-$111.78M-$3.03-4.50 Does the media favor ADUS or CELC? In the previous week, Addus HomeCare had 2 more articles in the media than Celcuity. MarketBeat recorded 4 mentions for Addus HomeCare and 2 mentions for Celcuity. Celcuity's average media sentiment score of 1.77 beat Addus HomeCare's score of 1.31 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Addus HomeCare 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is ADUS or CELC more profitable? Addus HomeCare has a net margin of 6.52% compared to Celcuity's net margin of 0.00%. Addus HomeCare's return on equity of 9.23% beat Celcuity's return on equity.Company Net Margins Return on Equity Return on Assets Addus HomeCare6.52% 9.23% 6.96% Celcuity N/A -96.21%-49.44% Do insiders and institutionals hold more shares of ADUS or CELC? 95.4% of Addus HomeCare shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 4.6% of Addus HomeCare shares are owned by insiders. Comparatively, 15.8% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, ADUS or CELC? Addus HomeCare has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Celcuity has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Do analysts rate ADUS or CELC? Addus HomeCare currently has a consensus price target of $142.57, suggesting a potential upside of 28.54%. Celcuity has a consensus price target of $28.40, suggesting a potential upside of 108.36%. Given Celcuity's higher possible upside, analysts clearly believe Celcuity is more favorable than Addus HomeCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addus HomeCare 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Celcuity 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryAddus HomeCare beats Celcuity on 13 of the 16 factors compared between the two stocks. Get Celcuity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELC vs. The Competition Export to ExcelMetricCelcuityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$516.11M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio-4.5020.8528.2320.27Price / SalesN/A298.79434.20100.92Price / CashN/A42.1137.1257.67Price / Book4.387.638.045.49Net Income-$111.78M-$55.05M$3.19B$250.45M7 Day Performance-1.16%8.43%3.62%4.78%1 Month Performance12.55%8.14%5.98%9.58%1 Year Performance-23.30%1.62%29.39%16.41% Celcuity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELCCelcuity2.2874 of 5 stars$13.63+0.1%$28.40+108.4%-23.3%$516.11MN/A-4.5040Positive NewsADUSAddus HomeCare4.9775 of 5 stars$110.62-1.1%$142.57+28.9%-8.3%$2.06B$1.15B24.9749,703PACSPACS Group2.8073 of 5 stars$12.51-4.8%$34.29+174.1%-59.2%$2.00B$3.11B0.0032,433ARDTArdent Health3.3506 of 5 stars$13.34-0.4%$20.67+54.9%N/A$1.92B$5.97B8.1824,900News CoverageAnalyst DowngradeLFSTLifeStance Health Group3.0982 of 5 stars$4.68-2.3%$8.50+81.6%-15.4%$1.86B$1.25B-46.8010,218News CoveragePGNYProgyny1.0845 of 5 stars$21.450.0%$23.45+9.3%-19.8%$1.84B$1.17B37.63310Trending NewsAnalyst UpgradeAnalyst RevisionGRALGRAIL0.6545 of 5 stars$44.85-4.0%$31.50-29.8%+175.0%$1.68B$125.60M-0.741,360NHCNational HealthCareN/A$104.23-3.9%N/A-14.6%$1.68B$1.37B13.0612,400News CoveragePositive NewsTDOCTeladoc Health2.6205 of 5 stars$8.06-2.8%$9.60+19.1%-11.3%$1.45B$2.57B-1.365,500News CoverageAnalyst ForecastVRDNViridian Therapeutics3.1935 of 5 stars$15.89+1.4%$37.56+136.3%+22.7%$1.28B$300K-4.1350News CoverageAHCOAdaptHealth3.3224 of 5 stars$9.25-0.8%$13.40+44.9%-13.1%$1.26B$3.26B16.2310,500 Related Companies and Tools Related Companies Addus HomeCare Competitors PACS Group Competitors Ardent Health Competitors LifeStance Health Group Competitors Progyny Competitors GRAIL Competitors National HealthCare Competitors Teladoc Health Competitors Viridian Therapeutics Competitors AdaptHealth Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELC) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celcuity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celcuity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CELC Stock Alerts